 RIGL hoped to expand the label of its drug Tavalisse fostamatinib, but the failure of the drug in phase 3 appeared to scupper its chances. RIGL sought guidance to see if a reanalysis of the failed phase 3 study might be well received, but it doesnt appear it was. 